Merck & Co., Inc. (MRK) stock forecast & analysis
145.27
NYSE · USDDelayed by 20 minutes
Down: -1.97, -1.3%
145.32Up: +0.05, +0.0%
1 analysis
Latest analysis: · verdict locked
- Open
- 145.02
- Previous close
- 147.24
- Day range
- 143.41 – 145.44
- 52-week range
- 82.01 – 156.92
- Volume (shares)
- 8.38M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 2.47B
- P/E ratio
- 115.29
- Dividend yield
- 2.34%
- Beta
- 0.22
- Market cap
- 358.41B
Market Scanner’s AI analysis of Merck & Co., Inc. (MRK), updated October 2026: Moderna's melanoma vaccine data leak and its impact on MRK's stock price were the primary focus of recent analyses.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Merck & Co., Inc. (MRK) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Moderna's melanoma vaccine data leak and its impact on MRK's stock price were the primary focus of recent analyses.
Recent analyses examined MRK's stock performance, noting its position relative to its 50-day and 200-day moving averages, and a flattening medium-term uptrend. The reports also covered a data leak concerning a melanoma cancer vaccine co-developed by MRK and Moderna, which led to a slip in MRK's share price.
MRK news & sentiment
News reports highlighted a significant share price drop for MRK following a leak of trial data for a co-developed melanoma cancer vaccine. The market reaction indicated negative sentiment surrounding the event.
MRK technical picture
MRK's stock closed below its 50-day SMA, but remained above its 200-day SMA, indicating a weakening medium-term trend alongside an intact long-term trend. Upside momentum was fading as the MACD histogram contracted after crossing above zero.
Fundamentals
The analyses covered MRK's valuation, noting its trailing and forward P/E ratios and dividend yield. The reports also tracked the stock's price relative to its 50-day and 200-day moving averages and its 52-week range.
Factors discussed — upside
- Long-term trend remains intact, indicated by the 200-day SMA well above price.
- MACD line crossed above zero, suggesting a shift in momentum.
- Low beta of 0.222 indicates low sensitivity to market moves.
Factors discussed — risks
- Medium-term uptrend is losing pace, with the 50-day SMA slope flattening.
- Upside momentum is fading, as indicated by the contracting MACD histogram.
- Trial data leak for a co-developed melanoma cancer vaccine impacted share price.
- stock performance
- vaccine development
- market momentum
Summary updated .
MRK technical indicators
Common technical indicators for MRK, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 146.64 | Price below |
| 10-day exponential moving average | 146.18 | Price below |
| Relative strength index (14-day) | 49.47 | Neutral |
| MACD line (12/26/9) | 0.4444 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 139.87 – 150.52 | Price inside the bands |
Analyses
Recent MRK.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-25 MRK.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Merck & Co., Inc.?
- The long-term trend remains intact, with the 200-day SMA well above price, and the MACD line crossing above zero suggests a shift in momentum. Additionally, the company's low beta indicates very low sensitivity to market moves.
- What are the risks for Merck & Co., Inc.?
- The medium-term uptrend is losing pace as the 50-day SMA slope flattens, and upside momentum appears to be fading. A recent data leak for a co-developed melanoma cancer vaccine also impacted the share price.
- Is Merck & Co., Inc. bullish or bearish?
- Recent AI analyses of Merck & Co., Inc. examined factors on both sides. Discussed upside: The long-term trend remains intact, with the 200-day SMA well above price, and the MACD line crossing above zero suggests a shift in momentum. Additionally, the company's low beta indicates very low sensitivity to market moves. Discussed risks: The medium-term uptrend is losing pace as the 50-day SMA slope flattens, and upside momentum appears to be fading. A recent data leak for a co-developed melanoma cancer vaccine also impacted the share price. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Merck & Co., Inc.?
- News reports highlighted a significant share price drop for MRK following a leak of trial data for a co-developed melanoma cancer vaccine. The market reaction indicated negative sentiment surrounding the event.
- How does Market Scanner analyse Merck & Co., Inc.?
- Every analysis of Merck & Co., Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Merck & Co., Inc.?
The long-term trend remains intact, with the 200-day SMA well above price, and the MACD line crossing above zero suggests a shift in momentum. Additionally, the company's low beta indicates very low sensitivity to market moves.
What are the risks for Merck & Co., Inc.?
The medium-term uptrend is losing pace as the 50-day SMA slope flattens, and upside momentum appears to be fading. A recent data leak for a co-developed melanoma cancer vaccine also impacted the share price.
Is Merck & Co., Inc. bullish or bearish?
Recent AI analyses of Merck & Co., Inc. examined factors on both sides. Discussed upside: The long-term trend remains intact, with the 200-day SMA well above price, and the MACD line crossing above zero suggests a shift in momentum. Additionally, the company's low beta indicates very low sensitivity to market moves. Discussed risks: The medium-term uptrend is losing pace as the 50-day SMA slope flattens, and upside momentum appears to be fading. A recent data leak for a co-developed melanoma cancer vaccine also impacted the share price. These are descriptive observations, not a recommendation.
What is the latest sentiment on Merck & Co., Inc.?
News reports highlighted a significant share price drop for MRK following a leak of trial data for a co-developed melanoma cancer vaccine. The market reaction indicated negative sentiment surrounding the event.
How does Market Scanner analyse Merck & Co., Inc.?
Every analysis of Merck & Co., Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- claude-medium-v2
Run a fresh MRK.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.